154 related articles for article (PubMed ID: 19775736)
1. Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.
Jandial DD; Messer K; Farshchi-Heydari S; Pu M; Howell SB
Gynecol Oncol; 2009 Dec; 115(3):362-6. PubMed ID: 19775736
[TBL] [Abstract][Full Text] [Related]
2. [The pharmacokinetics of intraperitoneal (IP) carboplatin (CBDCA) and dose-up study of intravenous (IV) cyclophosphamide (CPM) in combination with IP CBCDA for advanced ovarian cancer patients].
Fujiwara K; Yamauchi H; Sawada S; Koike H; Mohri H; Ohishi Y; Kohno I
Gan To Kagaku Ryoho; 1992 Dec; 19(14):2373-9. PubMed ID: 1463344
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion.
Lerza R; Vannozzi MO; Tolino G; Viale M; Bottino GB; Bogliolo G; Cerruti A; Castello G; Mencoboni M; Reggiardo G; Pannacciulli I; Esposito M
Ann Oncol; 1997 Apr; 8(4):385-91. PubMed ID: 9209670
[TBL] [Abstract][Full Text] [Related]
4. Nanoscopic tumor tissue distribution of platinum after intraperitoneal administration in a xenograft model of ovarian cancer.
Carlier C; Laforce B; Van Malderen SJM; Gremonprez F; Tucoulou R; Villanova J; De Wever O; Vincze L; Vanhaecke F; Ceelen W
J Pharm Biomed Anal; 2016 Nov; 131():256-262. PubMed ID: 27611097
[TBL] [Abstract][Full Text] [Related]
5. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
Blair BG; Larson CA; Safaei R; Howell SB
Clin Cancer Res; 2009 Jul; 15(13):4312-21. PubMed ID: 19509135
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics of carboplatin after intraperitoneal administration and clinical effect in ovarian cancer].
Ohno M; Hirokawa M; Hando T
Gan To Kagaku Ryoho; 1992 Dec; 19(14):2355-61. PubMed ID: 1463342
[TBL] [Abstract][Full Text] [Related]
7. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs.
Larson CA; Blair BG; Safaei R; Howell SB
Mol Pharmacol; 2009 Feb; 75(2):324-30. PubMed ID: 18996970
[TBL] [Abstract][Full Text] [Related]
8. [Usefulness of intraperitoneal carboplatin administration-- pharmacokinetic analysis].
Ito K; Itani Y; Furuki K; Tamori N; Noda T; Adachi S; Hirano Y; Kato Y; Kiyozuka Y
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Sep; 44(9):1180-6. PubMed ID: 1453047
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) by amphotericin B in BALB/c nude mice bearing human ovarian carcinoma cells.
Kojima M; Kikkawa F; Oguchi H; Tamakoshi K; Maeda O; Suganuma N; Tomoda Y
Jpn J Cancer Res; 1994 Nov; 85(11):1159-64. PubMed ID: 7829402
[TBL] [Abstract][Full Text] [Related]
10. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Holzer AK; Manorek GH; Howell SB
Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
[TBL] [Abstract][Full Text] [Related]
11. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
12. Effect of tumor presence on cisplatin and carboplatin: disposition in the isolated, perfused tumor and skin flap.
Vaden SL; Williams PL; Page RL; Riviere JE
Cancer Chemother Pharmacol; 1993; 32(1):31-8. PubMed ID: 8462121
[TBL] [Abstract][Full Text] [Related]
13. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy.
Los G; Verdegaal EM; Mutsaers PH; McVie JG
Cancer Chemother Pharmacol; 1991; 28(3):159-65. PubMed ID: 1855272
[TBL] [Abstract][Full Text] [Related]
14. Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action.
Los G; Verdegaal E; Noteborn HP; Ruevekamp M; de Graeff A; Meesters EW; ten Bokkel Huinink D; McVie JG
Biochem Pharmacol; 1991 Jul; 42(2):357-63. PubMed ID: 1859450
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor effects of redox-responsive nanoparticles containing platinum(Ⅳ)in ovarian cancer].
Hou HY; Tang DS; Zhang YN; Wang KY; Ao M; Luo HX; Li B
Zhonghua Zhong Liu Za Zhi; 2024 Jan; 46(1):76-85. PubMed ID: 38246783
[No Abstract] [Full Text] [Related]
16. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
17. Effect of hyperthermia on cisplatin and carboplatin disposition in the isolated, perfused tumour and skin flap.
Vaden SL; Page RL; Williams PL; Riviere JE
Int J Hyperthermia; 1994; 10(4):563-72. PubMed ID: 7963811
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.
Los G; Tuyt L; van Vugt M; Schornagel J; Pinedo HM
Cancer Chemother Pharmacol; 1993; 32(6):425-33. PubMed ID: 8258189
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells.
Misawa T; Kikkawa F; Maeda O; Obata NH; Higashide K; Suganuma N; Tomoda Y
Jpn J Cancer Res; 1995 Jan; 86(1):88-94. PubMed ID: 7737915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]